Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

  • ID: 3927999
  • Report
  • 416 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • BioLineRx, Ltd.
  • CrystalGenomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • NanoCarrier Co., Ltd.
  • Oryx GmbH & Co. KG
  • MORE
Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Summary

‘Metastatic Pancreatic Cancer - Pipeline Review, H2 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • BioLineRx, Ltd.
  • CrystalGenomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • NanoCarrier Co., Ltd.
  • Oryx GmbH & Co. KG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Metastatic Pancreatic Cancer Overview

Therapeutics Development

Pipeline Products for Metastatic Pancreatic Cancer - Overview

Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis

Metastatic Pancreatic Cancer - Therapeutics under Development by Companies

Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes

Metastatic Pancreatic Cancer - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Metastatic Pancreatic Cancer - Products under Development by Companies

Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes

Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development

AbbVie Inc

Aduro BioTech, Inc.

ArQule, Inc.

Array BioPharma Inc.

AstraZeneca Plc

Axcentua Pharmaceuticals AB

Berg LLC

BioLineRx, Ltd.

Bionomics Limited

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Clovis Oncology, Inc.

Cornerstone Pharmaceuticals, Inc.

CrystalGenomics, Inc.

CTI BioPharma Corp.

CytRx Corporation

Daiichi Sankyo Company, Limited

Eleison Pharmaceuticals LLC

Eli Lilly and Company

Ensol Biosciences Inc.

Erytech Pharma SA

F. Hoffmann-La Roche Ltd.

Fountain Biopharma Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Immodulon Therapeutics Ltd.

Incyte Corporation

MabVax Therapeutics Holdings, Inc.

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

NanoCarrier Co., Ltd.

NantKwest, Inc.

Natco Pharma Limited

NewLink Genetics Corporation

Novartis AG

Oncolytics Biotech Inc.

Oncovir, Inc.

Oryx GmbH & Co. KG

Pfizer Inc.

Pharmacyclics, Inc.

Phoenix Biotechnology, Inc.

Precision Biologics, Inc.

Rexahn Pharmaceuticals, Inc.

Silence Therapeutics Plc

Targovax ASA

Tiltan Pharma Ltd.

Tocagen Inc.

Zeria Pharmaceutical Co., Ltd.

Metastatic Pancreatic Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile

5B1-ADC - Drug Profile

acalabrutinib - Drug Profile

aldoxorubicin hydrochloride - Drug Profile

alpelisib - Drug Profile

ARQ-761 - Drug Profile

asparaginase - Drug Profile

atezolizumab - Drug Profile

Atu-027 - Drug Profile

avasimibe - Drug Profile

AXP-10711 - Drug Profile

BI-853520 - Drug Profile

binimetinib - Drug Profile

BL-8040 - Drug Profile

BNC-101 - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile

ceritinib - Drug Profile

CG-200745 - Drug Profile

Charis-1000 - Drug Profile

CIM-1 - Drug Profile

cisplatin - Drug Profile

CPI-613 - Drug Profile

dacomitinib - Drug Profile

ensituximab - Drug Profile

FB-704A - Drug Profile

flucytosine ER + vocimagene amiretrorepvec - Drug Profile

galunisertib - Drug Profile

glufosfamide - Drug Profile

GS-5745 - Drug Profile

GSK-2256098 - Drug Profile

haNK Program - Drug Profile

HuMab-5B1 - Drug Profile

ibrutinib - Drug Profile

IMM-101 - Drug Profile

INCB-52793 - Drug Profile

indoximod - Drug Profile

irinotecan hydrochloride - Drug Profile

istiratumab - Drug Profile

lapatinib ditosylate - Drug Profile

LCL-161 - Drug Profile

MesoCART - Drug Profile

MK-2206 - Drug Profile

MK-2206 + selumetinib sulfate - Drug Profile

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile

MVT-1075 - Drug Profile

napabucasin - Drug Profile

nimotuzumab - Drug Profile

NRCAN-019 - Drug Profile

olaparib - Drug Profile

paclitaxel albumin bound - Drug Profile

palbociclib - Drug Profile

Parvoryx - Drug Profile

PBI-05204 - Drug Profile

PCI-27483 - Drug Profile

pelareorep - Drug Profile

PLX-7486 - Drug Profile

Poly-ICLC - Drug Profile

PRI-724 - Drug Profile

RG-7876 - Drug Profile

ribociclib succinate - Drug Profile

rottlerin - Drug Profile

rucaparib camsylate - Drug Profile

RX-0201 - Drug Profile

SGT-53 - Drug Profile

Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile

sonidegib phosphate - Drug Profile

TG-01 - Drug Profile

TL-118 - Drug Profile

tosedostat - Drug Profile

trametinib dimethyl sulfoxide - Drug Profile

ubidecarenone - Drug Profile

ulixertinib - Drug Profile

ulocuplumab - Drug Profile

Vaccine for Oncology - Drug Profile

veliparib - Drug Profile

Z-360 - Drug Profile

Metastatic Pancreatic Cancer - Dormant Projects

Metastatic Pancreatic Cancer - Discontinued Products

Metastatic Pancreatic Cancer - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016

Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2016

Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Berg LLC, H2 2016

Metastatic Pancreatic Cancer - Pipeline by BioLineRx, Ltd., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2016

Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2016

Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2016

Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016

Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2016

Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Targovax ASA, H2 2016

Metastatic Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Tocagen Inc., H2 2016

Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Metastatic Pancreatic Cancer - Dormant Projects, H2 2016

Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H2 2016

Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H2 2016

Metastatic Pancreatic Cancer - Dormant Projects (Contd..3), H2 2016

Metastatic Pancreatic Cancer - Dormant Projects (Contd..4), H2 2016

Metastatic Pancreatic Cancer - Discontinued Products, H2 2016

Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H2 2016

Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H2 2016 402List of Figures

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016

Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • BioLineRx, Ltd.
  • CrystalGenomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • NanoCarrier Co., Ltd.
  • Oryx GmbH & Co. KG
  • MORE
Metastatic Pancreatic Cancer Pancreatic cancer that spreads to other organs is called metastatic pancreatic cancer. To kill cancer cells that have spread throughout the body, a systemic treatment is necessary, like chemotherapy. Signs and symptoms are upper abdominal pain that may radiate to your back, yellowing of your skin and the whites of your eyes (jaundice), loss of appetite, weight loss, depression, blood clots. Treatment includes surgery, radiation therapy and chemotherapy.

Metastatic Pancreatic Cancer pipeline therapeutics constitutes close to 78 molecules. Out of which approximately 72 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 40, 17, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 4 and 2 molecules, respectively.

Our latest report Metastatic Pancreatic Cancer – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
Aduro BioTech, Inc.
ArQule, Inc.
Array BioPharma Inc.
AstraZeneca Plc
Axcentua Pharmaceuticals AB
Berg LLC
BioLineRx, Ltd.
Bionomics Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Clovis Oncology, Inc.
Cornerstone Pharmaceuticals, Inc.
CrystalGenomics, Inc.
CTI BioPharma Corp.
CytRx Corporation
Daiichi Sankyo Company, Limited
Eleison Pharmaceuticals LLC
Eli Lilly and Company
Ensol Biosciences Inc.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
Fountain Biopharma Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Immodulon Therapeutics Ltd.
Incyte Corporation
MabVax Therapeutics Holdings, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
NanoCarrier Co., Ltd.
NantKwest, Inc.
Natco Pharma Limited
NewLink Genetics Corporation
Novartis AG
Oncolytics Biotech Inc.
Oncovir, Inc.
Oryx GmbH & Co. KG
Pfizer Inc.
Pharmacyclics, Inc.
Phoenix Biotechnology, Inc.
Precision Biologics, Inc.
Rexahn Pharmaceuticals, Inc.
Silence Therapeutics Plc
Targovax ASA
Tiltan Pharma Ltd.
Tocagen Inc.
Zeria Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll